Schnitzer, Thomas J.
Robinson, Rebecca L.
Tive, Leslie
Cappelleri, Joseph C.
Bushmakin, Andrew G.
Jackson, James
Berry, Mia
Barlow, Sophie
Walker, Chloe
Viktrup, Lars
Funding for this research was provided by:
Pfizer
Eli Lilly and Company
Article History
Received: 8 December 2021
Accepted: 4 May 2022
First Online: 26 May 2022
Declarations
:
: The Adelphi Disease Specific Programme (DSP) was performed in compliance with the United States Health Insurance Portability and Accountability Act 1996, and after review by the Western Institutional Review Board, the DSP methodology was granted ethical waiver. All patients provided informed consent.
: Not applicable.
: TJS reports clinical research study support (Pfizer, Lilly, Regeneron, Galapagos, Taiwan Liposome Corporation, Anika Therapeutics) and fees for consultancy/advisory boards (Pfizer, Lilly, GSK, AstraZeneca, Galapagos, Merck). RLR and LV are employees and stockholders of Eli Lilly and Company. JJ, MB, SB, and CW are employees of Adelphi Real World, which received funding from Pfizer and Eli Lilly and Company to conduct the study. LT, AGB, and JCC are employees of Pfizer with stock and/or stock options.